最近,HE Castagnino提出一个新的观点,以一种新的方法治疗心肌梗死(Int J Cardiol,1999,69:15)。传统的缺血性心脏病治疗的目的是以干预措施(搭桥术或经皮冠脉血管成形术)或药物增加心肌供氧,或减少氧的需求。然而,为了维持正常细胞的代谢能力和心肌收缩功能,给心肌适当供氧并非唯一的重要问题。 心肌细胞保护是一个新的治疗,可以达到血管再通的血流动力学效应,并可对氧的利用和细胞的完整性起作用。这是很引人注目的新概念,目前已经不断地进行研究,并在各方面取得了一些成绩。 然而,Castagnino关于心肌细胞保护的研究完全局限于人类生长激素(Ch),而没有扩展到更广泛的领域。虽然Gh可以有效地发挥细胞保护作用,但是不应只限于Gh治疗的研讨。早在1962年就曾经有报道关于应用葡萄糖、胰岛素 Recently, HE Castagnino came up with a new perspective on a new approach to treating myocardial infarction (Int J Cardiol, 1999, 69:15). The purpose of traditional ischemic heart disease treatment is to increase myocardial oxygen supply or to reduce oxygen demand with interventions (bypass or percutaneous coronary angioplasty) or drugs. However, proper oxygenation to the myocardium is not the only important issue in order to maintain normal cellular metabolism and myocardial contractility. Cardiomyocyte protection is a new treatment that achieves the hemodynamic effects of revascularization and can play a role in oxygen utilization and cell integrity. This is a very compelling new concept. At present, it has been continuously studied and made some achievements in various fields. However, Castagnino’s research on cardiomyocyte protection is completely confined to human growth hormone (Ch) and does not extend to a wider area. Although Gh can effectively play a cytoprotective role, but should not be limited to Gh treatment. As early as 1962 there have been reports on the application of glucose, insulin